Welcome to our dedicated page for Pulmatrix news (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix stock.
Pulmatrix, Inc. (PULM) generates news primarily as a clinical-stage biopharmaceutical company focused on inhaled therapeutics built on its patented iSPERSE™ dry powder technology. Company announcements frequently highlight developments in its pipeline of inhaled product candidates for central nervous system and respiratory diseases, including acute migraine, COPD and allergic bronchopulmonary aspergillosis.
News updates often cover clinical milestones for PUR3100, an orally inhaled dihydroergotamine (DHE) candidate for acute migraine, such as publication of Phase 1 results in a peer-reviewed journal and regulatory progress following FDA acceptance of an Investigational New Drug application and a “study may proceed” letter for a Phase 2 study. Pulmatrix also reports on PUR1800, a Narrow Spectrum Kinase Inhibitor for acute exacerbations in chronic obstructive pulmonary disease, including Phase 1b safety and tolerability data, and on PUR1900, its inhaled itraconazole formulation being advanced with partner Cipla outside the United States.
Investors following PULM news will also see regular corporate and strategic updates. These include quarterly and annual financial results, descriptions of cost-saving measures and Pulmatrix’s transition toward a more virtual operating model. The company has issued multiple releases about its proposed merger with Cullgen Inc., detailing stockholder approvals, regulatory steps such as the effectiveness of a registration statement on Form S-4, and conditions to closing, including Nasdaq and China Securities Regulatory Commission approvals. Pulmatrix has also reported entering into a mutual waiver agreement with Cullgen to allow both parties to explore alternative transactions while continuing to pursue the merger.
Additional news items describe licensing and collaboration activity, such as the cross-license agreement and facility transfer with MannKind Corporation involving iSPERSE™ and MannKind’s Cricket® inhalation device. For readers tracking PULM, this news page provides a centralized view of clinical data releases, regulatory filings referenced in press releases, strategic transactions and financial updates that shape the company’s evolution and its inhaled therapeutic programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pulmatrix, Inc. (NASDAQ: PULM) announced its 2022 financial results and corporate updates on March 30, 2023. The company reported revenue of $6.1 million, a 17% increase from $5.2 million in 2021, driven by collaborations. The year-end cash position stood at $35.6 million, providing a runway into Q2 2024. Significant milestones include the initiation of a Phase 2b study for PUR1900, with the first patient dosed in Q1 2023, and successful topline results for the Phase 1 study of PUR3100, showing promising safety and efficacy data. The company aims for further clinical studies for both PUR1900 and PUR3100.
Pulmatrix, Inc. (NASDAQ: PULM) announced the dosing of the first patient in a Phase 2b clinical trial for PUR1900, an inhaled treatment for Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. This double-blind, placebo-controlled study will assess the safety and efficacy of PUR1900 over 16 weeks, followed by an 8-week observation period. The trial aims to enroll 30 subjects across the U.S., U.K., Australia, and France. This milestone supports Pulmatrix's collaboration with Cipla and targets proof-of-concept data by mid-2024, potentially establishing PUR1900 as the first approved treatment for ABPA.
Pulmatrix, Inc. (NASDAQ: PULM) announces a virtual key opinion leader (KOL) event titled "PUR3100 for the Treatment of Acute Migraine: Unlocking Potential of DHE Treatment" on February 3, 2023, at 10:00 AM ET. The event features Dr. Stewart J. Tepper from Dartmouth College, discussing the treatment landscape for migraine patients and the clinical profile of dihydroergotamine (DHE). Dr. Margaret Wasilewski, CMO of Pulmatrix, will present recent Phase 1 data on PUR3100, an orally inhaled DHE delivered via Pulmatrix's patented iSPERSE™ technology. The event will include a live Q&A session.
Pulmatrix, Inc. (NASDAQ: PULM) announced that its abstract will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting from February 24-27, 2023 in San Antonio, Texas. The study focuses on PUR1800, an inhaled narrow-spectrum kinase inhibitor for chronic obstructive pulmonary disease (COPD). The presentation, by Margaret Wasilewski, MD, Chief Medical Officer, will summarize safety and tolerability results from a Phase 1b study. It is scheduled for a poster session on February 24 from 3:15 to 4:15 PM CST at the Convention Center, Lobby Level, Hall 2.